Literature DB >> 11177725

Relationship of Penicillin Resistance to Mortality in Pneumococcal Pneumonia.

Lionel A. Mandell1.   

Abstract

Clinical management of community-acquired pneumonia (CAP)--and Streptococcus pneumoniae infection in general--are controversial. Multiple sets of guidlines exist. This article reviews CAP, S. pneumoniae infection and drug resistance, the four sets of guidlines currently in use in North America, and the data upon which the agencies establishing those guidlines have based their consclusions, particularly about drug resistance and treatment failures. The article also considers the role of penicillin in the treatment of pneumococcal pneumonia.

Entities:  

Year:  2001        PMID: 11177725     DOI: 10.1007/s11908-001-0053-0

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  15 in total

1.  Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group.

Authors:  L A Mandell; T J Marrie; R F Grossman; A W Chow; R H Hyland
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

2.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

3.  Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.

Authors:  J D Heffelfinger; S F Dowell; J H Jorgensen; K P Klugman; L R Mabry; D M Musher; J F Plouffe; A Rakowsky; A Schuchat; C G Whitney
Journal:  Arch Intern Med       Date:  2000-05-22

4.  Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group.

Authors:  B J Marston; J F Plouffe; T M File; B A Hackman; S J Salstrom; H B Lipman; M S Kolczak; R F Breiman
Journal:  Arch Intern Med       Date:  1997 Aug 11-25

5.  Occurrence of Streptococcus pneumoniae meningitis during vancomycin and cefotaxime therapy of septicemia in a patient with sickle cell disease.

Authors:  P J Chesney; Y Davis; B K English; W C Wang
Journal:  Pediatr Infect Dis J       Date:  1995-11       Impact factor: 2.129

6.  Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia.

Authors:  S C Buckingham; S P Brown; V H Joaquin
Journal:  J Pediatr       Date:  1998-01       Impact factor: 4.406

7.  Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997.

Authors:  D R Feikin; A Schuchat; M Kolczak; N L Barrett; L H Harrison; L Lefkowitz; A McGeer; M M Farley; D J Vugia; C Lexau; K R Stefonek; J E Patterson; J H Jorgensen
Journal:  Am J Public Health       Date:  2000-02       Impact factor: 9.308

8.  Nosocomial epiglottitis associated with penicillin- and cephalosporin-resistant Streptococcus pneumoniae bacteremia.

Authors:  R S Daum; J P Nachman; C D Leitch; F C Tenover
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

9.  Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis.

Authors:  M J Fine; M A Smith; C A Carson; S S Mutha; S S Sankey; L A Weissfeld; W N Kapoor
Journal:  JAMA       Date:  1996-01-10       Impact factor: 56.272

10.  Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group.

Authors:  J F Plouffe; R F Breiman; R R Facklam
Journal:  JAMA       Date:  1996-01-17       Impact factor: 56.272

View more
  1 in total

1.  National study of antibiotic use in emergency department visits for pneumonia, 1993 through 2008.

Authors:  Mark I Neuman; Sarah A Ting; Ahou Meydani; Jonathan M Mansbach; Carlos A Camargo
Journal:  Acad Emerg Med       Date:  2012-05       Impact factor: 3.451

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.